In 2020, Zheng et al. screened LSD1 inhibitors from a complex library containing drugs approved by the US Food and Drug Administration (FDA) and identified the reversible inhibitor compound 107 (Figure 23A, IC50LSD1 = 0.9 μM, Fenoldopam), which can be used to treat renal cell carcinoma (RCC) [130]. This evidence concerns the gene KDM1A and renal cell carcinoma.